Respiratory syncytial virus infections - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Respiratory syncytial virus infections - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory syncytial virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Respiratory syncytial virus infections: Overview
Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.
'Respiratory syncytial virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory syncytial virus infections pipeline landscape is provided which includes the disease overview and Respiratory syncytial virus infections treatment guidelines. The assessment part of the report embraces, in depth Respiratory syncytial virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory syncytial virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Respiratory syncytial virus infections Emerging Drugs
Further product details are provided in the report..
Respiratory syncytial virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on following parameters that define the scope of the report, such as:
Respiratory syncytial virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory syncytial virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory syncytial virus infections drugs.
Respiratory syncytial virus infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Respiratory syncytial virus infections - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory syncytial virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Respiratory syncytial virus infections: Overview
Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.
'Respiratory syncytial virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory syncytial virus infections pipeline landscape is provided which includes the disease overview and Respiratory syncytial virus infections treatment guidelines. The assessment part of the report embraces, in depth Respiratory syncytial virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory syncytial virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus infections.
This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Respiratory syncytial virus infections Emerging Drugs
- GSK3844766A: GlaxoSmithKline
- Nirsevimab (MEDI-8897): MedImmune
- Sisunatovir: ReViral
Further product details are provided in the report..
Respiratory syncytial virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Respiratory syncytial virus infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Respiratory syncytial virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory syncytial virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory syncytial virus infections drugs.
Respiratory syncytial virus infections Report Insights
- Respiratory syncytial virus infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Respiratory syncytial virus infections drugs?
- How many Respiratory syncytial virus infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory syncytial virus infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Respiratory syncytial virus infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Respiratory syncytial virus infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- MedImmune
- ReViral
- Pfizer
- Sanofi
- BioComo
- IMV
- Shionogi
- Aridis Pharmaceuticals
- ADMA Biologics
- Enanta Pharmaceuticals
- Merck Sharp & Dohme
- Janssen Research & Development
- Ark Biosciences
- BlueWillow Biologics
- Meissa Vaccines
- Alios BioPharma
- Codagenix
- Advance Vaccine Laboratories
- Bavarian Nordic
- ModernaTX, Inc.
- Virometix
- Airway Therapeutics LLC
- AlloVir Inc
- Anima Biotech Inc
- Aridis Pharmaceuticals Inc
- Atea Pharmaceuticals Inc
- Atriva Therapeutics
- Calder Biosciences Inc
- Cidara Therapeutics Inc
- Clover Biopharmaceuticals
- Curevac AG
- Enyo Pharma SA
- HanaVax Inc.
- Icosavax Inc
- IDBiologics Inc
- Pneumagen Ltd
- Riboscience LLC
- Signia Therapeutics
- GSK3844766A
- Nirsevimab (MEDI-8897)
- Sisunatovir
- RSV F protein vaccine
- Novavax
- Combination seasonal influenza RSV nanoparticle vaccine
- NanoFlu/NVX CoV 2373/RSV
- RSVpreF
- SP 0125
- BC-0004
- GSK 3888550A
- DPX RSV Vaccine
- AR 201
- ASCENIV
- EDP 938
- MK 1654
- Rilematovir
- GSK 3003891A
- JNJ 64400141
- Ziresovir
- JNJ 64213175
- MV-012-968
- ALS-008176
- CodaVax-RSV
- BARS13
- MVA-BN-RSV
- mRNA-1345
- V-306
- ALVR106
- AR-201
- AT-889
- ATR-002
- IVX-121
- RBS-3149
Introduction
Executive Summary
Respiratory syncytial virus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Respiratory syncytial virus infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Respiratory syncytial virus infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Respiratory syncytial virus infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
GSK3844766A: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
EDP 938: Enanta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
mRNA-1345: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
AR-201: Aridis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Respiratory syncytial virus infections Key Companies
Respiratory syncytial virus infections Key Products
Respiratory syncytial virus infections- Unmet Needs
Respiratory syncytial virus infections- Market Drivers and Barriers
Respiratory syncytial virus infections- Future Perspectives and Conclusion
Respiratory syncytial virus infections Analyst Views
Respiratory syncytial virus infections Key Companies
Appendix
Executive Summary
Respiratory syncytial virus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Respiratory syncytial virus infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Respiratory syncytial virus infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Respiratory syncytial virus infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
GSK3844766A: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
EDP 938: Enanta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
mRNA-1345: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
AR-201: Aridis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Respiratory syncytial virus infections Key Companies
Respiratory syncytial virus infections Key Products
Respiratory syncytial virus infections- Unmet Needs
Respiratory syncytial virus infections- Market Drivers and Barriers
Respiratory syncytial virus infections- Future Perspectives and Conclusion
Respiratory syncytial virus infections Analyst Views
Respiratory syncytial virus infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Respiratory syncytial virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Respiratory syncytial virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Respiratory syncytial virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Respiratory syncytial virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products